Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Bristol Myers Squibb

Tracked across 38 events · 927 articles · First seen Sep 26, 2025 · Last active Sep 23, 2026

Sentiment
15
Attention
8
Events
38
Relationships
12
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 40
Business
Impact: BMS is deploying the most powerful Nvidia AI infrastructure in life sciences, aiming to compress drug discovery timelines and improve pipeline success rates. The investment builds on a three-year collaboration and is expected to enhance its competitive position in AI-driven R&D.
Jul 20, 2026 · 14 articles
7 30
Business
Impact: Bristol Myers Squibb is the target of the potential merger, which would provide it with a significant premium and access to AstraZeneca's pipeline. Its shares have risen 43% in the past year, and the deal could further boost its valuation.
Aug 02, 2026 · 60 articles
4 60
Business
Impact: Bristol Myers Squibb is the primary investor, committing $2.3 billion to build a new manufacturing campus in United States — Houston. This investment is part of its $40 billion U.S. expansion plan and is expected to enhance its manufacturing capabilities and support future drug production.
Aug 10, 2026 · 20 articles
2 40
Business
Impact: Bristol Myers Squibb is a key player in the antibody therapeutics market, benefiting from the projected market growth.
Jul 28, 2026 · 6 articles
8 30
Tech
Impact: Bristol Myers Squibb>>>'s immunotherapies Opdivo and Yervoy are mentioned as potentially faring better when patients are also taking GLP-1 drugs, suggesting a possible interaction with the immune system.
Jun 02, 2026 · 45 articles
3 55
Tech
Impact: Founding and major contributing member; provides pharmaceutical expertise and data.
Jul 13, 2026 · 6 articles
4 -10
Business
Impact: Bristol Myers voluntarily paused Zola-cel studies as a precaution, reflecting broader industry caution in CAR-T autoimmune therapies.
Sep 01, 2026 · 7 articles
4 20
Regulatory
The United States — United States Department of the Treasury is drafting rules governing US pharmaceutical companies' investments in China that would likely preserve their ability to strike most licensing deals for Chinese drugs, according…
Impact: Bristol Myers Squibb signed a partnership with Jiangsu Hengrui worth up to $15.2 billion this year, a deal type the draft rules would likely preserve.
Sep 18, 2026 · 6 articles
1 0
Business
Impact: Bristol Myers Squibb divests CeeNU in Canada, a minor portfolio adjustment.
Jul 15, 2026 · 8 articles
4 50
Tech
Impact: Bristol Myers Squibb is jointly developing pumitamig with BioNTech, which is being used in the clinical trial collaboration with Boehringer Ingelheim.
Apr 09, 2026 · 6 articles
6 5
Regulatory
Impact: Bristol Myers Squibb is one of the major drugmakers that has reached pricing agreements with the Donald Trump administration to avoid the new tariffs.
Apr 02, 2026 · 23 articles
4 20
Business
Impact: Bristol Myers Squibb is a partner of Optellum in the US, supporting the commercial momentum of Optellum's AI solutions in lung cancer care.
Jun 04, 2026 · 6 articles
2 10
Business
Impact: Bristol Myers Squibb is participating in the Kinaxis conference as a speaker, sharing insights on navigating disruption and improving operational outcomes in supply chain management.
May 28, 2026 · 6 articles
3 20
Business
Impact: Bristol Myers Squibb had an executive, Anvita Karara, recognized with an Ignite Leadership Award for driving enterprise-wide AI transformations within the company.
Jun 25, 2026 · 8 articles
2 30
Tech
Impact: Bristol Myers Squibb is a consortium member. The publication may influence its approach to cognitive endpoints in neurodegenerative disease trials.
Aug 18, 2026 · 6 articles
7 40
Business
Impact: Reportedly in merger talks with AstraZeneca, which could create a $400 billion drugmaker.
Jul 14, 2026 · 280 articles
4 10
Business
Impact: Bristol Myers Squibb is a pharmaceutical company that participates in the OpenFold consortium, benefiting from access to AI-enabled tools for drug discovery.
Jun 10, 2026 · 9 articles
4 20
Regulatory
Impact: Bristol Myers Squibb supported Gilead's appeal, gaining from the precedent that reduces innovation-related legal risks.
Aug 03, 2026 · 6 articles
4 50
Business
Impact: Bristol Myers Squibb is mentioned as another pharmaceutical company partnering with AI firms, but this event does not directly impact it.
Aug 10, 2026 · 7 articles
4 5
Tech
Anthropic has quietly established a wet lab in the San Francisco Bay Area to conduct physical biology experiments, moving beyond computer-based in silico research into hands-on drug science. The lab's existence was confirmed by Eric…
Impact: Reached an arrangement giving its workforce access to Claude for research and development.
Sep 18, 2026 · 22 articles
4 5
Business
Impact: Bristol Myers Squibb is a drug sponsor engaged with Cellares' Cell Shuttle platform and has a $380 million global manufacturing agreement with Cellares, reserving commercial-scale capacity.
Jun 15, 2026 · 6 articles
4 0
Business
Novo Nordisk and Anthropic announced a collaboration on September 16, 2026, aimed at accelerating the development of new medicines using Anthropic's Claude AI models and the Claude Science research workbench. The Danish drugmaker will initially…
Impact: Bristol Myers Squibb is cited as having a prior arrangement with Anthropic giving its workforce access to Claude, providing context for the Novo Nordisk deal.
Sep 16, 2026 · 20 articles
2 0
Regulatory
Multiple investor-rights law firms have filed securities fraud class actions against Replimune Group (NASDAQ: REPL) and certain of its officers, alleging violations of federal securities laws during the class period of October 20, 2025 to…
Impact: Its PD-1 inhibitor Opdivo was the combination partner in the rejected RP1 BLA; the rejection is a minor setback to one combination program within a large diversified portfolio.
Jul 29, 2026 · 139 articles
4 0
Business
Telix Pharmaceuticals agreed to acquire privately held ITM Isotope Technologies Munich in a deal valued at up to $2.35 billion, comprising $1.65 billion upfront plus up to $700 million in contingent milestone payments. The upfront…
Impact: Cited as a recent acquirer of radiopharmaceutical assets, part of the broader M&A trend in the industry.
Sep 21, 2026 · 6 articles
4 0
Regulatory
Impact: Bristol Myers Squibb has a presence in Hyderabad with R&D and capability centers, contributing to India — Telangana's life sciences ecosystem.
Jan 21, 2026 · 6 articles
3 0
Business
Impact: Bristol Myers Squibb originally licensed bempikibart to Q32 Bio; no direct impact from this event.
Jul 13, 2026 · 6 articles
4 0
Business
Impact: Bristol Myers Squibb is mentioned as a prior acquirer in the sector, highlighting the trend of radiopharmaceutical consolidation.
Aug 03, 2026 · 7 articles
4 0
Business
Impact: Bristol Myers Squibb was mentioned in the context of brief merger speculation involving AstraZeneca, which triggered investor backlash but is not directly part of this event.
Aug 17, 2026 · 20 articles
7 30
Regulatory
Impact: Bristol Myers Squibb, another KRAS inhibitor developer, is similarly affected by the competitive landscape.
Aug 26, 2026 · 92 articles
4 0
International
UK Prime Minister Andy Burnham used his first United Nations General Assembly address in New York to declare 'Britain is back' and set out a foreign policy vision centered on AI governance, Russian disinformation, and…
Impact: Christopher Boerner attended Burnham's business event; no direct impact.
Sep 22, 2026 · 22 articles
+ 8 more events View on Dashboard
Eli Lilly and Company ↔ Bristol Myers Squibb
Eli Lilly and Company ↔ Bristol Myers Squibb
AstraZeneca ↔ Bristol Myers Squibb
AstraZeneca ↔ Bristol Myers Squibb
Merck & Co. ↔ Bristol Myers Squibb
Merck & Co. ↔ Bristol Myers Squibb
United States ↔ Bristol Myers Squibb
United States ↔ Bristol Myers Squibb
Donald Trump ↔ Bristol Myers Squibb
Donald Trump ↔ Bristol Myers Squibb
ERGEN INTELLIGENCE
Track Bristol Myers Squibb live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.